Salud financiera de hoja de balance de SciVision Biotech
Salud financiera controles de criterios 6/6
SciVision Biotech tiene un patrimonio de accionistas total de NT$1.8B y una deuda total de NT$137.0M, lo que sitúa su ratio deuda-patrimonio en 7.5%. Sus activos y pasivos totales son NT$2.1B y NT$321.6M respectivamente. El BAIT de SciVision Biotech es de NT$249.1M, por lo que su ratio de cobertura de intereses es de -18.4. Tiene efectivo e inversiones a corto plazo que ascienden a NT$782.4M.
Información clave
7.5%
Ratio deuda-patrimonio
NT$137.00m
Deuda
| Ratio de cobertura de intereses | -18.4x |
| Efectivo | NT$782.42m |
| Patrimonio | NT$1.82b |
| Total pasivo | NT$321.64m |
| Activos totales | NT$2.15b |
Actualizaciones recientes sobre salud financiera
SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Recent updates
Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?
Oct 11SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Aug 30SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's
Jul 22SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50
Jun 28SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Jun 14SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio
Apr 01Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital
Apr 02Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?
Mar 15Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Feb 25Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?
Feb 05Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?
Jan 01
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years
Dec 14Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Nov 25Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (NT$1.0B) de 1786 superan a sus pasivos a corto plazo (NT$123.4M).
Pasivo a largo plazo: Los activos a corto plazo de 1786 (NT$1.0B) superan a sus pasivos a largo plazo (NT$198.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 1786 tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de 1786 ha pasado de 21.8% a 7.5% en los últimos 5 años.
Cobertura de la deuda: La deuda de 1786 está bien cubierta por el flujo de caja operativo (183%).
Cobertura de intereses: 1786 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.